Clinical journal of oncology nursing最新文献

Background: Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), alone or in combination with immune checkpoint inhibitors, are part of the standard of care in treating metastatic renal cell carcinoma (mRCC). VEGFR-TKIs are associated with acute, chronic, and potentially dose-limiting toxicities requiring treatment modifications and discontinuations.

Objectives: This article summarizes evidence-based practices that oncology nurses may use to manage VEGFR-TKI adverse events and improve quality of life in patients with mRCC.

Methods: Pivotal clinical trial publications of VEGFR-TKIs in mRCC were reviewed to evaluate the adverse event profile of each drug and effective management strategies.

Findings: Patients with mRCC treated with VEGFR-TKIs can benefit from education about potential side effects, consistent monitoring, and early detection of adverse events, as well as appropriate interventions to improve treatment tolerability, adherence, outcomes, and quality of life.

As a nurse educator, scientist, and scholar, I am passionate about raising awareness of the importance of self-advocacy. Listen to your body. Do not dismiss your intuition. Take an active role in your health care, rather than.

Toilet plume aerosols are a source of hazardous drug (HD) contamination in patient bathrooms; however, using plastic-backed pads to reduce contamination has not been tested within the clinical setting. This study tested wheth.

This article discusses the intersection of domestic abuse and cancer, particularly in couples experiencing breast and gynecologic cancers, and its impact on patients in Africa. It aims to uncover the challenges faced in this.

Palliative care can lead to improved quality of life and often extends life, particularly when it begins early in the cancer care continuum. Even with these positive outcomes, many clinicians do not use palliative care early.

Background: Radiation therapy is the main treatment method for esophageal cancer, but its side effects are not ideal. The interprofessional team (IPT) management model has been widely applied in clinical practice; however, there are few reports on nurse-led IPT-based enteral nutrition intervention strategies for patients with esophageal cancer.

Objectives: A nurse-led, IPT-based, whole-course enteral nutrition intervention was investigated to determine whether it could achieve better nutritional status, quality of life, and treatment efficacy for patients with esophageal cancer.

Methods: A total of 72 patients with esophageal cancer were randomized to control and IPT groups. Nutritional status, quality of life, and treatment efficacy were observed before and after radiation therapy.

Findings: Severe malnutrition and grade 3 or higher bone marrow suppression had significantly lower incidence, and the one-year progression-free and overall survival rates of patients were significantly higher in the IPT group than the control group.

For men receiving androgen deprivation therapy for prostate cancer, exercise is essential to preserve lean muscle mass, body mass, and bone density, which may be lost as a side effect of treatment. This quality improvement pr.

Background: Although risk factors have been identified and certain treatment plans require premedications to prevent reactions, it remains uncertain which patient will have an antineoplastic infusion-related reaction (IRR), and there is no way to predict the severity of that reaction.

Objectives: This article highlights details of these risks and emphasizes interventions to identify, prevent, minimize, and manage IRRs in adult ambulatory cancer treatment settings.

Methods: Using the mnemonic PRIMER (prevention, recognition, intervention, management, evaluation, and recommendation), this article outlines key topics for infusion centers to ensure safe, high-quality care for high-risk patients.

Findings: Using a standardized, evidence-based IRR algorithm based on the PRIMER model can optimize outcomes for patients who experience antineoplastic IRRs.

Background: Although allogeneic hematopoietic stem cell transplantation (alloHSCT) can be a lifesaving therapy for patients with hematologic malignancies, only 30% of patients in need of transplantation will have a human leukocyte antigen matched related donor available.

Objectives: This article introduces an approved alternative donor stem cell source that is shown to provide earlier engraftment and decreased infections compared to dual or single umbilical cord blood transplantation.

Methods: This article provides an overview of the pathophysiology, clinical trial results, and nursing management of the approved omidubicel-onlv cellular therapy product as an alternative donor source for patients undergoing alloHSCT.

Findings: Omidubicel provides an alternative donor source for patients undergoing alloHSCT for whom there is no matched donor available. This need may be particularly great in ethnic and racial minority populations who may be underrepresented in the NMDP BioTherapies database.

Germline biomarker testing of the TP53 gene can produce confusing results including mosaicism or clonal hematopoiesis of indeterminate potential (CHIP). When noninformative results are reported, additional testing is usually.